Myrtelle Inc. has commenced commercial-stage manufacturing for its investigational gene therapy product, MYR-101, developed for the treatment of Canavan disease. The initiative marks a key milestone in the company’s journey toward market readiness and expanded patient access. The manufacturing programme
Viralgen and the CTNNB1 Foundation have announced a collaboration to develop an investigational gene therapy for CTNNB1 Syndrome, a rare neurodevelopmental disorder that affects motor and cognitive function. The therapy, produced using Viralgen’s AAV manufacturing platform, is expected to advance
Viralgen and Axovia Therapeutics have announced a collaboration to advance the development and production of an investigational gene therapy targeting Bardet-Biedl Syndrome (BBS), a genetic condition causing progressive vision loss and multi-system disorders. The partnership aims to address the needs
